Основная статистика
| CIK | 1825413 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Biotech Acquisition Co - Units (1 Ord Class A & 1/2 War)
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| February 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1) Biotech Acquisition Company (Name of Issuer) Class A ordinary shares, par value $0.0001 per share (Title of Class of Securities) G1125A108 ( |
|
| February 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number: 001-39935 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specifie |
|
| February 14, 2023 |
BIOT / Biotech Acquisition Company Class A / GLAZER CAPITAL, LLC Passive Investment SC 13G 1 biot20221231.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Biotech Acquisition Company (Name of Issuer) Class A ordinary share, $0.0001 par value per share (Title of Class of Securities) G1125A108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat |
|
| February 13, 2023 |
BIOT / Biotech Acquisition Company Class A / ARISTEIA CAPITAL LLC Passive Investment SC 13G/A 1 sc13gabiotechacquisition.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) Biotech Acquisition Company (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G1125A108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of thi |
|
| February 13, 2023 |
BIOT / Biotech Acquisition Company Class A / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biotech Acquisition Company (Name of Issuer) Class A Ordinary Shares, par value $0.0001 (Title of Class of Securities) G1125A108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa |
|
| February 2, 2023 |
Biotech Acquisition Company Announces Liquidation Exhibit 99.1 Biotech Acquisition Company Announces Liquidation New York, New York, Feb. 01, 2023 (GLOBE NEWSWIRE) - Biotech Acquisition Company (the “Company”) (Nasdaq: BIOT), announced today that it will not implement the extension of the time period the Company has to complete an initial business combination as approved by its shareholders at an extraordinary general meeting of shareholders held |
|
| February 2, 2023 |
Termination of a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 1, 2023 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commis |
|
| January 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. ) Biotech Acquisition Company (Name of Issuer) Class A ordinary shares, par value $0.0001 per share (Title of Class of Securities) G1125A108 (C |
|
| January 25, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 19, 2023 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commis |
|
| January 25, 2023 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biotech Acquisition Company (Name of Issuer) Class A Ordinary Shares, $0.0001 par value (Title of Class of Securities) G1125A108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 9, 2023 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commiss |
|
| January 4, 2023 |
DEF 14A 1 def14a0123biotechacq.htm PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commiss |
|
| December 22, 2022 |
Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): December 21, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commi |
|
| December 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| November 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 BIOTECH ACQUISITI |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-39935 (Check One): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-CEN ? Form N-CSR For Period Ended: September 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report |
|
| October 11, 2022 |
Promissory Note of the Company to Cryfield Investments, Ltd. dated October 4, 2022 Exhibit 10.2 THIS PROMISSORY NOTE (?NOTE?) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY |
|
| October 11, 2022 |
Promissory Note of the Company to Biotech Sponsor LLC dated October 4, 2022 Exhibit 10.1 THIS PROMISSORY NOTE (?NOTE?) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE ?SECURITIES ACT?). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER THE SECURITIES ACT OR AN OPINION OF COUNSEL REASONABLY SATISFACTORY IN FORM, SCOPE AND SUBSTANCE TO THE COMPANY |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): October 11, 2022 (October 4, 2022) BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of inco |
|
| August 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 BIOTECH ACQUISITION CO |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-39935 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on F |
|
| June 17, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 17, 2022 (June 14, 2022) BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorpora |
|
| June 17, 2022 |
Biotech Acquisition Company 545 West 25th Street, 20th Floor New York, New York 10001 Biotech Acquisition Company 545 West 25th Street, 20th Floor New York, New York 10001 June 17, 2022 Via EDGAR U. |
|
| June 13, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Biotech Acquisition Company and Blade Therapeutics Mutually Agree to Terminate Business Combination Agreement NEW YORK and SOUTH SAN FRANCISCO, Calif., June 13, 2022 ? Biotech Acquisition Company (NASDAQ: BIOT) (?BAC?), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, and Blade Therapeutics, Inc. (?Blade?), a biophar |
|
| June 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2022 (June 10, 2022) BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorpora |
|
| June 13, 2022 |
Exhibit 10.1 TERMINATION AND RELEASE AGREEMENT THIS TERMINATION AND RELEASE AGREEMENT, dated as of June 10, 2022 (this ?Agreement?), is entered into by and among Biotech Acquisition Company, a Cayman Islands exempted company (together with its successors, the ?Acquiror?), Blade Merger Subsidiary, Inc., a Delaware corporation and a wholly-owned subsidiary of the Acquiror (?Merger Sub?), Biotech Spo |
|
| June 3, 2022 |
Exhibit 99.1 Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination ? Extraordinary General Meeting of BAC?s shareholders postponed until a to-be-determined later date NEW YORK and SOUTH SAN FRANCISCO, Calif., June 2, 2022 ? Biotech Acquisition Company (NASDAQ: BIOT) (?BAC?), a publicly traded speci |
|
| June 3, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| June 3, 2022 |
Exhibit 99.1 Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination ? Extraordinary General Meeting of BAC?s shareholders postponed until a to-be-determined later date NEW YORK and SOUTH SAN FRANCISCO, Calif., June 2, 2022 ? Biotech Acquisition Company (NASDAQ: BIOT) (?BAC?), a publicly traded speci |
|
| June 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 2, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 31, 2022 |
Exhibit 99.1 Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination ? Extraordinary General Meeting of BAC?s shareholders postponed until June 3, 2022, at 10:00 a.m., Eastern Time NEW YORK and SOUTH SAN FRANCISCO, Calif., May 31, 2022 ? Biotech Acquisition Company (NASDAQ: BIOT) (?BAC?), a publicly |
|
| May 31, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 31, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 31, 2022 |
Exhibit 99.1 Biotech Acquisition Company and Blade Therapeutics Announce Postponement of Extraordinary Meeting of Shareholders to Approve Proposed Business Combination ? Extraordinary General Meeting of BAC?s shareholders postponed until June 3, 2022, at 10:00 a.m., Eastern Time NEW YORK and SOUTH SAN FRANCISCO, Calif., May 31, 2022 ? Biotech Acquisition Company (NASDAQ: BIOT) (?BAC?), a publicly |
|
| May 24, 2022 |
Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: May 24, 2022 a. Press Release On May 24, 2022, Biotech Acquisition Company (?BAC?) ? which is a party to a previously disclosed Agreement and Plan of Merge |
|
| May 24, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration Statement No. 333-263577 PROXY STATEMENT for an Extraordinary General Meeting of BIOTECH ACQUISITION COMPANY (a Cayman Islands exempted company) PROSPECTUS SUPPLEMENT May 23, 2022 for 90,548,487 Shares of Common Stock and 11,500,000 Redeemable Warrants of BIOTECH ACQUISITION COMPANY (such securities to be issued after the Company?s re-domestication in |
|
| May 23, 2022 |
Exhibit 2.1 Amendment to Agreement and Plan of Merger This Amendment (this ?Amendment?), entered into and effective as of May 17, 2022, is made to that certain Agreement and Plan of Merger (the ?Original Agreement?; as amended by this Amendment and as the same may be further amended, modified and restated, the ?Merger Agreement?) dated as of November 8, 2021, by and among Biotech Acquisition Compa |
|
| May 23, 2022 |
Exhibit 2.1 Amendment to Agreement and Plan of Merger This Amendment (this ?Amendment?), entered into and effective as of May 17, 2022, is made to that certain Agreement and Plan of Merger (the ?Original Agreement?; as amended by this Amendment and as the same may be further amended, modified and restated, the ?Merger Agreement?) dated as of November 8, 2021, by and among Biotech Acquisition Compa |
|
| May 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2022 (May 17, 2022) BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporati |
|
| May 23, 2022 |
Financial Statements and Exhibits, Entry into a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 23, 2022 (May 17, 2022) BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporati |
|
| May 19, 2022 |
Filed by Biotech Acquisition Company Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: May 19, 2022 a. Social Media On May 19, 2022, Blade shared the following on its LinkedIn page: The American Thoracic Society 2022 International Conference |
|
| May 18, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference ? Cudetaxestat displayed direct anti-fibrotic effects on multiple biomarkers in a preclinical lung fibrosis model ? Non-competitive autotaxin inhibition by cudetaxestat maintained potency in the p |
|
| May 18, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 18, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 18, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 18, 2022 |
Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: May 18, 2022 a. Press Release On May 18, 2022, Blade Therapeutics, Inc. (?Blade?) ? which is a party to a previously disclosed Agreement and Plan of Merger |
|
| May 18, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Blade Therapeutics Presents Preclinical Data Highlighting Differentiating Characteristics of Cudetaxestat at the American Thoracic Society 2022 International Conference ? Cudetaxestat displayed direct anti-fibrotic effects on multiple biomarkers in a preclinical lung fibrosis model ? Non-competitive autotaxin inhibition by cudetaxestat maintained potency in the p |
|
| May 17, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference ? No significant drug-drug interaction (DDI) seen with cudetaxestat in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF) ? Cudetaxestat was well tolerat |
|
| May 17, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 17, 2022 |
Exhibit 99.1 FOR IMMEDIATE RELEASE Blade Therapeutics Presents Data from Phase 1 and Preclinical Studies of Cudetaxestat at the American Thoracic Society 2022 International Conference ? No significant drug-drug interaction (DDI) seen with cudetaxestat in combination with either pirfenidone or nintedanib, two approved therapies for idiopathic pulmonary fibrosis (IPF) ? Cudetaxestat was well tolerat |
|
| May 17, 2022 |
Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: May 17, 2022 a. Press Release On May 16, 2022, Blade Therapeutics, Inc. (?Blade?) ? which is a party to a previously disclosed Agreement and Plan of Merger |
|
| May 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 17, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2022 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 BIOTECH ACQUISITION C |
|
| May 16, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2022 |
Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Corporate Presentation May 16, 2022 Disclaimer and Other Important Information 2 This Presentation (the ?Presentation?) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics, Inc. (the ?Target?). The Target and Biotech Acquisition C |
|
| May 16, 2022 |
Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Corporate Presentation May 16, 2022 Disclaimer and Other Important Information 2 This Presentation (the ?Presentation?) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics, Inc. (the ?Target?). The Target and Biotech Acquisition C |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 16, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 16, 2022 |
BIOT / Biotech Acquisition Company Class A / Beryl Capital Management LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Biotech Acquisition Company (Name of Issuer) Class A Ordinary Shares, par value $0.0001 (Title of Class of Securities) G1125A108 (CUSIP Number) May 6, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| May 13, 2022 |
Filed by Biotech Acquisition Company 425 1 ea159948-425biotech.htm FORM 425 Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: May 13, 2022 a. Open Letter to the Respiratory Community On May 13, 2022, Blade Therapeutics, Inc. (“Blade”) – which |
|
| May 10, 2022 |
Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: May 9, 2022 a. Press Release On May 9, 2022, Biotech Acquisition Company (?BAC?) ? which is a party to a previously disclosed Agreement and Plan of Merger, |
|
| May 9, 2022 |
As filed with the United States Securities and Exchange Commission on May 9, 2022. As filed with the United States Securities and Exchange Commission on May 9, 2022. |
|
| May 9, 2022 |
Filed Pursuant to Rule 424(b)(3) Registration No. 333-263577 PROXY STATEMENT for an Extraordinary General Meeting of BIOTECH ACQUISITION COMPANY (a Cayman Islands exempted company) PROSPECTUS for 90,548,487 Shares of Common Stock and 11,500,000 Redeemable Warrants of BIOTECH ACQUISITION COMPANY (such securities to be issued after the Company?s re-domestication in the State of Delaware and its rena |
|
| May 9, 2022 |
Biotech Acquisition Company 545 West 25th Street, 20th Floor New York, NY 10001 May 9, 2022 Biotech Acquisition Company 545 West 25th Street, 20th Floor New York, NY 10001 May 9, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2022 (May 3, 2022) BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation |
|
| May 9, 2022 |
425 1 ea159623-8k425biotech.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 9, 2022 (May 3, 2022) BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/ |
|
| May 6, 2022 |
May 6, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| May 4, 2022 |
Exhibit 10.27 Execution Version REGISTRATION RIGHTS AGREEMENT This REGISTRATION RIGHTS AGREEMENT (this ?Agreement?), dated as of May 3, 2022, is by and between CF Principal Investments LLC, a Delaware limited liability company (the ?Investor?), and Biotech Acquisition Company, a Cayman Islands exempted company (the ?Company?). RECITALS A. The Company and the Investor have entered into that certain |
|
| May 4, 2022 |
As filed with to the United States Securities and Exchange Commission on May 3, 2022. As filed with to the United States Securities and Exchange Commission on May 3, 2022. |
|
| May 4, 2022 |
Consent of Michael Shleifer to be named as a director Exhibit 99.9 Consent to be Named as a Director In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and |
|
| May 4, 2022 |
Exhibit 10.26 Execution Version COMMON STOCK PURCHASE AGREEMENT This COMMON STOCK PURCHASE AGREEMENT is made and entered into as of May 3, 2022 (this ?Agreement?), by and between CF Principal Investments LLC, a Delaware limited liability company (the ?Investor?), and Biotech Acquisition Company, a Cayman Islands exempted company (the ?Company?). RECITALS WHEREAS, the Company has entered into an Ag |
|
| May 4, 2022 |
Specimen Common Stock Certificate of Blade Biotherapeutics, Inc. Exhibit 4.5 The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM ? as tenants in common UNIF GIFT MIN ACT ? Custodian TEN ENT ? as tenants by the entireties (Cust) (Minor) IT TEN ? as joint tenants with right of survivorship and not as tenants in com |
|
| April 18, 2022 |
Exhibit 10.22 March 24, 2022 Felix Karim, Ph.D. 732 Laurel Drive Walnut Creek, CA 94596 Re: Proposed Compensation Adjustments Dear Felix: Blade Therapeutics, Inc. (the ?Company?) would like to amend the terms of your employment (and your underlying offer letter dated September 30, 2016 (the ?Offer Letter?)) as set forth in this letter (this ?Agreement?) to reflect the following adjustments to your |
|
| April 18, 2022 |
Exhibit 10.18 30 September 2016 Dear Felix, Congratulations! On behalf of Blade Therapeutics, Inc. (the ?Company?), I am pleased to set forth below the terms of your employment with the Company. Should you accept our offer: 1. You will be employed to serve on a full-time basis as Executive Vice President, Business Development, responsible for such duties as are consistent with such position, plus |
|
| April 18, 2022 |
Exhibit 10.20 March 24, 2022 Jean-Fr?d?ric Viret, Ph.D. 337 Thompson Avenue Mountain View, CA 94043 Re: Proposed Compensation Adjustments Dear Jean: Blade Therapeutics, Inc. (the ?Company?) would like to amend the terms of your employment (and your underlying offer letter dated February 1, 2021 (the ?Offer Letter?) as set forth in this letter (this ?Agreement?) to reflect the following adjustments |
|
| April 18, 2022 |
April 15, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| April 18, 2022 |
Consent of John A. Hohneker, M.D. to be named as a director Exhibit 99.7 Consent to be Named as a Director In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and |
|
| April 18, 2022 |
Consent of Luke Evnin to be named as a director Exhibit 99.6 Consent to be Named as a Director In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and |
|
| April 18, 2022 |
Consent of Carl Goldfischer, M.D. to be named as a director Exhibit 99.8 Consent to be Named as a Director In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and |
|
| April 18, 2022 |
Exhibit 10.21 March 24, 2022 Prabha Ibrahim, Ph.D. 3380 Lubich Drive Mountain View, CA 94040 Re: Proposed Compensation Adjustments Dear Prabha: Blade Therapeutics, Inc. (the ?Company?) would like to amend the terms of your employment (and your underlying offer letter dated April 19, 2017 (the ?Offer Letter?)) as set forth in this letter (this ?Agreement?) to reflect the following adjustments to yo |
|
| April 18, 2022 |
EX-10.15 4 fs42022a2ex10-15biotechacq.htm OFFER LETTER, DATED AS OF JULY 18, 2016, BY AND BETWEEN BLADE THERAUEPTICS, INC. AND WENDYE ROBBINS, M.D Exhibit 10.15 BLADE THERAPEUTICS, INC. July 18, 2016 Wendye Robbins, M.D. 181 28th Avenue San Francisco, CA 94121 Dear Wendye: I am pleased to offer you a full-time position with Blade Therapeutics, Inc. (the “Company”) as the Company’s Chief Executive |
|
| April 18, 2022 |
Consent of Mark Timney to be named as a director Exhibit 99.3 Consent to be Named as a Director In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and |
|
| April 18, 2022 |
Exhibit 10.19 March 24, 2022 Wendye Robbins, M.D. 181 28th Avenue San Francisco, CA 94121 Re: Proposed Compensation Adjustments Dear Wendye: Blade Therapeutics, Inc. (the ?Company?) would like to amend the terms of your employment (and your underlying offer letter dated July 7, 2016 (the ?Offer Letter?)) as set forth in this letter (this ?Agreement?) to reflect the following adjustments to your co |
|
| April 18, 2022 |
Exhibit 10.17 19 April 2017 Dear Prabha, Congratulations! On behalf of Blade Therapeutics, Inc. (the ?Company?), I am pleased to set forth below the terms of your employment with the Company. Should you accept our offer: 1. You will be employed as Chief Technical Officer, responsible for developing and communicating the technical vision of the Company. You will be responsible for driving all non-c |
|
| April 18, 2022 |
Consent of Wendye Robbins to be named as a director Exhibit 99.2 Consent to be Named as a Director In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and |
|
| April 18, 2022 |
Exhibit 10.16 February 1, 2021 Jean-Fr?d?ric Viret, Ph.D. Dear Jean: I am pleased to offer you a full-time position with Blade Therapeutics, Inc. (the ?Company?) as the Company?s Chief Financial Officer. This letter agreement sets forth the terms and conditions of your appointment as Chief Financial Officer of the Company, effective as of March 15, 2021 (the ?Start Date?). Capitalized terms used h |
|
| April 18, 2022 |
As filed with to the United States Securities and Exchange Commission on April 15, 2022. |
|
| April 18, 2022 |
Consent of James Scopa to be named as a director Exhibit 99.5 Consent to be Named as a Director In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and |
|
| April 18, 2022 |
Consent of Lloyd Klickstein to be named as a director Exhibit 99.4 Consent to be Named as a Director In connection with the filing by Biotech Acquisition Company of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and |
|
| April 11, 2022 |
EX-99.1 2 ea158285ex99-1biotechacq.htm INVESTOR PRESENTATION Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Corporate Presentation April 2022 Disclaimer and Other Important Information 2 This Presentation (the “Presentation”) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics |
|
| April 11, 2022 |
Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Corporate Presentation April 2022 Disclaimer and Other Important Information 2 This Presentation (the “Presentation”) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics, Inc. (the “Target”). The Target and Biotech Acquisition Com |
|
| April 11, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| April 11, 2022 |
425 1 ea158285-425biotech.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 11, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdicti |
|
| April 5, 2022 |
425 1 ea158018-425biotechacq.htm FORM 425 Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: April 5, 2022 a. Press Release On April 4, 2022, Biotech Acquisition Company (“BAC”) – which is a party to a prev |
|
| April 4, 2022 |
Blade Therapeutics Announces Feedback from FDA on End-of-Phase 1 Data Package Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: April 4, 2022 a. Press Release On April 4, 2022, Blade Therapeutics, Inc. (“Blade”) – which is a party to a previously disclosed Agreement and Plan of Merg |
|
| April 4, 2022 |
As filed with to the United States Securities and Exchange Commission on April 1, 2022. As filed with to the United States Securities and Exchange Commission on April 1, 2022. |
|
| April 1, 2022 |
April 1, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| March 31, 2022 |
Filed by Biotech Acquisition Company Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: March 30, 2022 a. Poster Presentation at the Society of Toxicology Annual Meeting On March 30, 2022, Blade Therapeutics, Inc. (“Blade”) – which is a party |
|
| March 24, 2022 |
Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: March 24, 2022 a. Press Release On March 24, 2022, Blade Therapeutics, Inc. (?Blade?) ? which is a party to a previously disclosed Agreement and Plan of Me |
|
| March 15, 2022 |
As filed with to the United States Securities and Exchange Commission on March 15, 2022. As filed with to the United States Securities and Exchange Commission on March 15, 2022. |
|
| March 15, 2022 |
EX-99.1 2 ea156873ex99-1biotech.htm INVESTOR PRESENTATION Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Corporate Presentation March 2022 Disclaimer and Other Important Information 2 This Presentation (the “Presentation”) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics, I |
|
| March 15, 2022 |
March 15, 2022 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| March 15, 2022 |
EX-99.1 2 ea156871ex99-1biotech.htm OPPENHEIMER PRESENTATION Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Oppenheimer’s 32 nd Annual Healthcare Conference Wendye Robbins, M.D. President & CEO February 15, 2022 Disclaimer and Other Important Information 2 This Presentation (the “Presentation”) is for informational purposes only to assist |
|
| March 15, 2022 |
List of subsidiaries of the Registrant Exhibit 21.1 Entity Jurisdiction Blade Merger Subsidiary, Inc. Delaware |
|
| March 15, 2022 |
Exhibit 10.21 FIRST AMENDMENT TO LEASE This FIRST AMENDMENT TO LEASE (?First Amendment?) is made and entered into as of October 15, 2021, by and between BAYSIDE ACQUISITION, LLC, a Delaware limited liability company (?Landlord?), and BLADE THERAPEUTICS, INC., a Delaware corporation (?Tenant?). R E C I T A L S: A. Landlord and Tenant are parties to the Lease dated April 28, 2016 (the ?Lease?), purs |
|
| March 15, 2022 |
425 1 ea156871-8k425biotech.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or |
|
| March 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| March 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| March 15, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| March 15, 2022 |
EX-10.22 4 fs42022ex10-22biotechacq.htm SUBLEASE AGREEMENT, DATED AS OF OCTOBER 1, 2019, BY AND AMONG BLADE THERAPEUTICS, INC. AND MOLECULAR TRANSPORT INC. Exhibit 10.22 SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of October 1, 2019, and is made by and between Blade Therapeutics, Inc., a Delaware corporation (“Sublessor”), and Applied Molecular Transport Inc., a Del |
|
| March 15, 2022 |
EX-99.2 3 ea156873ex99-2biotech.htm PRESS RELEASE Exhibit 99.2 Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc. New York, NY, March 15, 2022 – Biotech Acquisition Company (NASDAQ: BIOT) (“BAC”), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today annou |
|
| March 15, 2022 |
Calculation of Filing Fees Table Exhibit 107 Calculation of Filing Fee Tables Form S-4 (Form Type) Biotech Acquisition Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities CALCULATION OF REGISTRATION FEE Security Type Security Class Title(1) Fee Calculation Rule(3) Amount Being Registered Proposed Maximum Offering Price Per Security Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common Stock(2) (3) 457(f)(1) 32,250,000 $9. |
|
| March 15, 2022 |
Form of Proxy Card for Extraordinary General Meeting Exhibit 99.1 YOUR VOTE IS IMPORTANT. PLEASE VOTE TODAY. Vote by Internet - QUICK EASY IMMEDIATE - 24 Hours a Day, 7 Days a Week or by Mail BIOTECH ACQUISITION COMPANY Your Internet vote authorizes the named proxies to vote your shares in the same manner as if you marked, signed and returned your proxy card. Votes submitted electronically over the Internet must be received by 11:59 p.m., Eastern Ti |
|
| March 15, 2022 |
Exhibit 99.2 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Barclay?s Global Healthcare Conference Wendye Robbins, M.D. President & CEO February 16, 2022 Disclaimer and Other Important Information 2 This Presentation (the ?Presentation?) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics, |
|
| March 15, 2022 |
Exhibit 99.2 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Barclay?s Global Healthcare Conference Wendye Robbins, M.D. President & CEO February 16, 2022 Disclaimer and Other Important Information 2 This Presentation (the ?Presentation?) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics, |
|
| March 15, 2022 |
Exhibit 99.2 Biotech Acquisition Company Announces Public Filing of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc. New York, NY, March 15, 2022 ? Biotech Acquisition Company (NASDAQ: BIOT) (?BAC?), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has publicly filed, with the U.S. Sec |
|
| March 15, 2022 |
EX-99.1 2 ea156873ex99-1biotech.htm INVESTOR PRESENTATION Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Corporate Presentation March 2022 Disclaimer and Other Important Information 2 This Presentation (the “Presentation”) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics, I |
|
| March 15, 2022 |
EX-99.1 2 ea156871ex99-1biotech.htm OPPENHEIMER PRESENTATION Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Oppenheimer’s 32 nd Annual Healthcare Conference Wendye Robbins, M.D. President & CEO February 15, 2022 Disclaimer and Other Important Information 2 This Presentation (the “Presentation”) is for informational purposes only to assist |
|
| March 15, 2022 |
Consent of Vantage Point Advisors, Inc. Exhibit 99.9 Consent of Vantage Point Advisors, Inc. We hereby consent to (i) the inclusion of our opinion letter, dated October 25, 2021, to the Board of Directors of Biotech Acquisition Company (?BAC?) as Annex G to Proxy Statement/Prospectus which forms a part of the Registration Statement on Form S-4 related to the proposed merger with Blade Therapeutics, Inc. and (ii) the references to such o |
|
| March 15, 2022 |
EX-10.20 2 fs42022ex10-20biotechacq.htm BRITANNIA LIFE SCIENCE CENTER LEASE, DATED AS OF APRIL 28, 2016, BY AND AMONG BLADE THERAPEUTICS, INC. AND BAYSIDE ACQUISITION, LLC Exhibit 10.20 BRITANNIA LIFE SCIENCE CENTER LEASE This Lease (the “Lease”), dated as of the date set forth in Section 1 of the Summary of Basic Lease Information (the “Summary”), below, is made by and between BAYSIDE ACQUISITION |
|
| March 8, 2022 |
EX-99.1 2 ea156396ex99-1biotechacq.htm AUDITED BALANCE SHEET AS OF JANUARY 28, 2021 (RESTATED) Exhibit 99.1 INDEX TO FINANCIAL STATEMENT Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and the Board of Directors of Biotech Acquisition Company Opinion o |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 BIOTECH ACQUISITI |
|
| March 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2022 (January 28, 2021) BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or |
|
| March 8, 2022 |
Code of Ethics and Business Conduct.* EX-14.1 2 f10k2021ex14-1biotechacq.htm CODE OF ETHICS AND BUSINESS CONDUCT Exhibit 14.1 CODE OF ETHICS AND BUSINESS CONDUCT OF BIOTECH ACQUISITION COMPANY 1. Introduction The Board of Directors (the “Board”) of Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), has adopted this code of ethics and business conduct (this “Code”), as may be amended from time to time by th |
|
| March 7, 2022 |
Blade Therapeutics to Participate in Upcoming Investor Conferences Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: March 7, 2022 a. Press Release On March 7, 2022, Blade Therapeutics, Inc. (“Blade”) – which is a party to a previously disclosed Agreement and Plan of Merg |
|
| February 22, 2022 |
Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Corporate Presentation February 2022MB0 Disclaimer and Other Important Information 2 This Presentation (the ?Presentation?) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics, Inc. (the ?Target?). The Target and Biotech Acquisiti |
|
| February 22, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commi |
|
| February 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 22, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commi |
|
| February 22, 2022 |
EX-99.2 3 ea156010ex99-2biotech.htm ANALYST PRESENTATION Exhibit 99.2 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Blade Analyst Day February 22, 2022 Welcome! The event will start shortly. Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Blade Analyst Day February 22, 2022 Disclaimer and Other Important |
|
| February 22, 2022 |
Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Corporate Presentation February 2022MB0 Disclaimer and Other Important Information 2 This Presentation (the ?Presentation?) is for informational purposes only to assist interested parties in evaluating the busi nes s of Blade Therapeutics, Inc. (the ?Target?). The Target and Biotech Acquisiti |
|
| February 22, 2022 |
Exhibit 99.2 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Blade Analyst Day February 22, 2022 Welcome! The event will start shortly. Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases Blade Analyst Day February 22, 2022 Disclaimer and Other Important Information 3 This Presentation (the “Presentation”) is f |
|
| February 14, 2022 |
BIOT / Biotech Acquisition Company Class A / ARISTEIA CAPITAL LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. *) Biotech Acquisition Company (Name of Issuer) Class A Ordinary Shares, Included as Part of the Units (Title of Class of Securities) G1125A108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box |
|
| February 14, 2022 |
BIOT / Biotech Acquisition Company Class A / Biotech Sponsor LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Biotech Acquisition Company (Name of Issuer) Class A Ordinary Shares, par value $0.0001 per share (Title of Class of Securities) G1125A108 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box t |
|
| January 12, 2022 |
Exhibit 99.3 LinkedIn posting announcing positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat co-administered with approved IPF therapies Target Posting Date: January 12, 2022 Post Text Today we announced the successful completion of a phase 1 drug-drug interaction clinical study that evaluated co-administration of cudetaxestat with either of two approved thera |
|
| January 12, 2022 |
Exhibit 99.2 FOR IMMEDIATE RELEASE Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis ? Clinical study found that cudetaxestat, a non-competitive inhibitor of autotaxin, was well tolerated and showed no reports of drug-related serious adverse events or |
|
| January 12, 2022 |
Exhibit 99.2 FOR IMMEDIATE RELEASE Blade Therapeutics Announces Successful Completion of Phase 1 Clinical Study that Evaluated Co-Administration of Cudetaxestat with Either of Two Approved Therapies for Idiopathic Pulmonary Fibrosis ? Clinical study found that cudetaxestat, a non-competitive inhibitor of autotaxin, was well tolerated and showed no reports of drug-related serious adverse events or |
|
| January 12, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commis |
|
| January 12, 2022 |
Exhibit 99.3 LinkedIn posting announcing positive topline data from a phase 1 drug-drug interaction clinical study of cudetaxestat co-administered with approved IPF therapies Target Posting Date: January 12, 2022 Post Text Today we announced the successful completion of a phase 1 drug-drug interaction clinical study that evaluated co-administration of cudetaxestat with either of two approved thera |
|
| January 12, 2022 |
Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases January 2022 Disclaimer and Other Important Information 2 This Presentation (the ?Presentation?) is for informational purposes only to assist interested parties in evaluating a propos ed initial business combination (the ?Transaction? or ?Business Combination?) between Biotech Acquisition Com |
|
| January 12, 2022 |
EX-99.1 2 ea153875ex99-1biotech.htm INVESTOR PRESENTATION Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases January 2022 Disclaimer and Other Important Information 2 This Presentation (the “Presentation”) is for informational purposes only to assist interested parties in evaluating a propos ed initial business combination (the “Transaction” |
|
| January 12, 2022 |
425 1 ea153875-8k425biotech.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 12, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State |
|
| January 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commiss |
|
| January 3, 2022 |
Exhibit 99.1 Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc. New York, NY, January 3, 2022 ? Biotech Acquisition Company (NASDAQ: BIOT) (?BAC?), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential su |
|
| January 3, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 3, 2022 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commiss |
|
| January 3, 2022 |
Exhibit 99.1 Biotech Acquisition Company Announces Confidential Submission of Registration Statement on Form S-4 Related to Proposed Merger with Blade Therapeutics, Inc. New York, NY, January 3, 2022 ? Biotech Acquisition Company (NASDAQ: BIOT) (?BAC?), a publicly traded special purpose acquisition company affiliated with SPRIM Global Investments, today announced that it has made a confidential su |
|
| December 27, 2021 | ||
| December 27, 2021 |
Confidential Treatment Requested by Biotech Acquisition Company Pursuant to 17 C.F.R. Section 200.83 DRS 1 filename1.htm Confidential Treatment Requested by Biotech Acquisition Company Pursuant to 17 C.F.R. Section 200.83 As confidentially submitted to the United States Securities and Exchange Commission on December , 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-4 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biotech Acquisit |
|
| December 27, 2021 |
Exhibit 21.1 Entity Jurisdiction Blade Merger Subsidiary, Inc. Delaware |
|
| December 14, 2021 |
BIOTU / Biotech Acquisition Company Unit / Atalaya Capital Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Biotech Acquisition Company (Name of Issuer) Class A Common Stock, par value $0.0001 per share (Title of Class of Securities) G1125A124** (CUSIP Number) October 1, 2021*** (Date of Event which Requires Filing of this Statement) Check the appropriate box |
|
| November 30, 2021 |
Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: November 30, 2021 a. Press Release On November 30, 2021, Blade Therapeutics, Inc. (?Blade?) - which is party to a previously disclosed Agreement and Plan o |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 BIOTECH ACQUISITI |
|
| November 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): November 15, 2021 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commi |
|
| November 15, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-39935 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: September 30, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report |
|
| November 9, 2021 |
Filed by Biotech Acquisition Company 425 1 ea150286-425biotechacq.htm 425 Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: November 9, 2021 On November 9, Ivan Jarry, who is the Chief Operating Officer of Biotech Acquisition Company, through |
|
| November 8, 2021 |
EX-2.1 2 ea148645ex2-1biotechacqui.htm AGREEMENT AND PLAN OF MERGER, DATED AS OF NOVEMBER 8, 2021, BY AND AMONG BIOTECH ACQUISITION COMPANY, BLADE MERGER SUBSIDIARY, INC., BLADE THERAPEUTICS, INC., BIOTECH SPONSOR LLC Exhibit 2.1 CONFIDENTIAL Execution Version AGREEMENT AND PLAN OF MERGER by and among BIOTECH ACQUISITION COMPANY, as the Acquiror, BLADE MERGER SUBSIDIARY, INC., as Merger Sub, BIOTE |
|
| November 8, 2021 |
EX-99.1 8 ea148645ex99-1biotechacqui.htm INVESTOR PRESENTATION, DATED NOVEMBER , 2021 Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases November 2021 Disclaimer and Other Important Information 2 This Presentation (the “Presentation”) is for informational purposes only to assist interested parties in evaluating a propos ed initial business co |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2021 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2021 |
Exhibit 99.2 Biotech Acquisition Company and Blade Therapeutics Definitive Merger Agreement Investor Presentation Transcript, November 2021 Slide 1 (00:00) Michael Shleifer: Hello. Thank you for joining us. I?m Michael Shleifer, CEO and chairman of Biotech Acquisition Corporation and co-founder and managing partner of SPRIM Global Investments. I?m joined by Dr. Wendye Robbins, president and CEO of |
|
| November 8, 2021 |
Exhibit 2.1 CONFIDENTIAL Execution Version AGREEMENT AND PLAN OF MERGER by and among BIOTECH ACQUISITION COMPANY, as the Acquiror, BLADE MERGER SUBSIDIARY, INC., as Merger Sub, BIOTECH SPONSOR LLC, solely with respect to and for purposes of Section 3.05 in the capacity as the Acquiror Representative, jean-fr?d?ric viret, solely with respect to and for purposes of Section 3.05 in the capacity as th |
|
| November 8, 2021 |
EX-99.2 9 ea148645ex99-2biotechacqui.htm TRANSCRIPT, DATED NOVEMBER , 2021 Exhibit 99.2 Biotech Acquisition Company and Blade Therapeutics Definitive Merger Agreement Investor Presentation Transcript, November 2021 Slide 1 (00:00) Michael Shleifer: Hello. Thank you for joining us. I’m Michael Shleifer, CEO and chairman of Biotech Acquisition Corporation and co-founder and managing partner of SPRIM |
|
| November 8, 2021 |
Exhibit 10.3 Biotech Sponsor LLC 545 West 25th Street, 20th Floor New York, NY 10001 November 8, 2021 Biotech Acquisition Corp. 545 West 25th Street, 20th Floor New York, NY 10001 Attn: Ivan Jarry, Chief Operating Officer Email: [email protected] Blade Therapeutics, Inc. 442 Littlefield Avenue South San Francisco, CA 94080 Attn: Dr. Wendye R. Robbins, CEO; Jean-Fr?d?ric Viret, CFO E-mail: wrobb |
|
| November 8, 2021 |
EX-10.3 5 ea148645ex10-3biotechacqui.htm SPONSOR AGREEMENT, DATED AS OF NOVEMBER 8, 2021, BY AND BETWEEN BIOTECH ACQUISITION COMPANY, BLADE THERAPEUTICS, INC., AND BIOTECH SPONSOR LLC Exhibit 10.3 Biotech Sponsor LLC 545 West 25th Street, 20th Floor New York, NY 10001 November 8, 2021 Biotech Acquisition Corp. 545 West 25th Street, 20th Floor New York, NY 10001 Attn: Ivan Jarry, Chief Operating Of |
|
| November 8, 2021 |
Filed by Biotech Acquisition Company pursuant to Rule 425 under the U.S. Securities Act of 1933, as amended, under the Securities Exchange Act of 1934, as amended Subject Company: Biotech Acquisition Company Commission File No.: 001-39935 Date: November 8, 2021 On November 8, 2021, Biotech Acquisition Company (?BAC?), which is party to a previously disclosed Agreement and Plan of Merger, dated as |
|
| November 8, 2021 |
EX-10.5 7 ea148645ex10-5biotechacqui.htm FORM OF AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT, DATED AS OF NOVEMBER 8, 2021, BY AND AMONG BIOTECH ACQUISITION COMPANY, BIOTECH SPONSOR LLC, AND CERTAIN EQUITYHOLDERS OF BLADE THERAPEUTICS, INC Exhibit 10.5 FORM OF AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated |
|
| November 8, 2021 |
EX-10.1 3 ea148645ex10-1biotechacqui.htm FORM OF VOTING AGREEMENT, DATED AS OF NOVEMBER 8, 2021, BY AND AMONG BIOTECH ACQUISITION COMPANY, BLADE THERAPEUTICS, INC., AND THE STOCKHOLDERS OF BLADE THERAPEUTICS, INC. PARTY THERETO Exhibit 10.1 Execution Version FORM OF VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made as of November 8, 2021, by and among (i) Biotech Acquisition Compan |
|
| November 8, 2021 |
Exhibit 10.4 FORM OF SUBSCRIPTION AGREEMENT This subscription agreement (this ?Subscription Agreement?) is being entered into as of November 8, 2021, by and between Biotech Acquisition Company, a Cayman Islands exempted company (together with any successor thereto, including after the Domestication (defined below), the ?Company?), and the undersigned subscriber (?Subscriber?). WHEREAS, this Subscr |
|
| November 8, 2021 |
Exhibit 10.1 Execution Version FORM OF VOTING AGREEMENT This Voting Agreement (this ?Agreement?) is made as of November 8, 2021, by and among (i) Biotech Acquisition Company, a company incorporated as a Cayman Islands exempted company (together with its successors, including after the Conversion (as defined below), the ?Acquiror?), (ii) Blade Therapeutics, Inc., a Delaware corporation (?Blade?), a |
|
| November 8, 2021 |
EX-99.3 10 ea148645ex99-3biotechacqui.htm PRESS RELEASE, DATED NOVEMBER 8, 2021 Exhibit 99.3 Biotech Acquisition Company and Blade Therapeutics Announce Definitive Merger Agreement ● Proposed merger to create publicly traded biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases ● Combined company expected to have post-trans |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): November 8, 2021 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commis |
|
| November 8, 2021 |
Exhibit 99.1 Developing Cutting - Edge Treatments for Debilitating Fibrotic and Neurodegenerative Diseases November 2021 Disclaimer and Other Important Information 2 This Presentation (the ?Presentation?) is for informational purposes only to assist interested parties in evaluating a propos ed initial business combination (the ?Transaction? or ?Business Combination?) between Biotech Acquisition Co |
|
| November 8, 2021 |
EX-10.5 7 ea148645ex10-5biotechacqui.htm FORM OF AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT, DATED AS OF NOVEMBER 8, 2021, BY AND AMONG BIOTECH ACQUISITION COMPANY, BIOTECH SPONSOR LLC, AND CERTAIN EQUITYHOLDERS OF BLADE THERAPEUTICS, INC Exhibit 10.5 FORM OF AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT THIS AMENDED AND RESTATED REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated |
|
| November 8, 2021 |
Exhibit 10.2 FORM OF LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (this ?Agreement?) is made and entered into as of November 8, 2021 by and between (i) Biotech Acquisition Company, a Cayman Islands exempted company (together with its successors, including after the Conversion (as defined below), ?Acquiror?), and (ii) the undersigned Blade Stockholder (?Holder?). Any capitalized term used but not defin |
|
| November 8, 2021 |
EX-10.2 4 ea148645ex10-2biotechacqui.htm FORM OF LOCK-UP AGREEMENT, DATED AS OF NOVEMBER 8, 2021, BY AND BETWEEN BIOTECH ACQUISITION COMPANY AND THE STOCKHOLDERS OF BLADE THERAPEUTICS, INC. PARTY THERETO Exhibit 10.2 FORM OF LOCK-UP AGREEMENT THIS LOCK-UP AGREEMENT (this “Agreement”) is made and entered into as of November 8, 2021 by and between (i) Biotech Acquisition Company, a Cayman Islands ex |
|
| November 8, 2021 |
EX-99.3 10 ea148645ex99-3biotechacqui.htm PRESS RELEASE, DATED NOVEMBER 8, 2021 Exhibit 99.3 Biotech Acquisition Company and Blade Therapeutics Announce Definitive Merger Agreement ● Proposed merger to create publicly traded biopharmaceutical company focused on developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases ● Combined company expected to have post-trans |
|
| November 8, 2021 |
Exhibit 10.4 FORM OF SUBSCRIPTION AGREEMENT This subscription agreement (this ?Subscription Agreement?) is being entered into as of November 8, 2021, by and between Biotech Acquisition Company, a Cayman Islands exempted company (together with any successor thereto, including after the Domestication (defined below), the ?Company?), and the undersigned subscriber (?Subscriber?). WHEREAS, this Subscr |
|
| August 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended June 30, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 BIOTECH ACQUISITION CO |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): May 21, 2021 BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commission |
|
| May 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 BIOTECH ACQUISITION C |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING Commission File Number: 001-39935 (Check one): ? Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form 10-D ? Form N-SAR ? Form N-CSR For Period Ended: March 31, 2021 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on |
|
| March 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 BIOTECH ACQUISITI |
|
| March 23, 2021 |
Description of Registered Securities* Exhibit 4.5 DESCRIPTION OF EACH CLASS OF SECURITIES REGISTERED UNDER SECTION 12 OF THE EXCHANGE ACT As of December 31, 2020, Biotech Acquisition Company (“we,” “our,” “us” or the “Company”) had no securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). As of January 25, 2021, we had the following three classes of securities registered under S |
|
| March 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 17, 2021 Biotech Acquisition Company (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or other jurisdiction of incorporation) (Commissi |
|
| March 15, 2021 |
Exhibit 99.1 Biotech Acquisition Company Announces Separate Trading of its Class A Ordinary Shares and Warrants Commencing March 18, 2021 NEW YORK, NY, March 15, 2021 – Biotech Acquisition Company (NASDAQ: BIOTU) (the “Company”) announced that, commencing March 18, 2021, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary |
|
| March 15, 2021 |
Other Events, Financial Statements and Exhibits 8-K 1 ea137600-8kbiotechacq.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 15, 2021 Biotech Acquisition Company (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State or |
|
| March 11, 2021 |
Quarterly Report - QUARTERLY REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (MARK ONE) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarter ended September 30, 2020 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-39935 BIOTECH ACQUISITI |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 3, 2021 |
Financial Statements and Exhibits, Other Events 8-K 1 ea134464-8kbiotechacquis.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 3, 2021 (January 28, 2021) BIOTECH ACQUISITION COMPANY (Exact name of registrant as specified in its charter) Cayman |
|
| February 3, 2021 |
EX-99.1 2 ea134464ex99-1biotechacquis.htm AUDITED BALANCE SHEET AS OF JANUARY 28, 2021 Exhibit 99.1 INDEX TO FINANCIAL STATEMENT Audited Financial Statements for Biotech Acquisition Company: Page Report of Independent Registered Public Accounting Firm F-2 Balance Sheet F-3 Notes to Financial Statement F-4 F-1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Shareholders and the Board |
|
| January 29, 2021 |
Biotech Acquisition Company Announces Closing of $230,000,000 Initial Public Offering EX-99.2 11 ea134164ex99-2biotechacq.htm PRESS RELEASE, DATED JANUARY 28, 2021 Exhibit 99.2 Biotech Acquisition Company Announces Closing of $230,000,000 Initial Public Offering New York, NY, January 28, 2021 (GLOBE NEWSWIRE) – Biotech Acquisition Company (the “Company”) announced today that it has closed its initial public offering of 23,000,000 units, including 3,000,000 units issued pursuant to |
|
| January 29, 2021 |
Amended and Restated Memorandum and Articles of Association. (1) Exhibit 3.1 THE COMPANIES ACT (As Revised) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF Biotech Acquisition Company (adopted by special resolution dated 25 JANUARY 2021 and effective on 25 JANUARY 2021) THE COMPANIES ACT (As Revised) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF Bi |
|
| January 29, 2021 |
EX-4.1 4 ea134164ex4-1biotechacq.htm WARRANT AGREEMENT, DATED JANUARY 25, 2021, BY AND BETWEEN THE COMPANY AND CONTINENTAL STOCK TRANSFER & TRUST COMPANY, AS WARRANT AGENT Exhibit 4.1 WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of January 25, 2021, is by and between Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), and Continental Stock Trans |
|
| January 29, 2021 |
Exhibit 10.2 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of January 25, 2021, by and between Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”). WHEREAS, the Company’s registration statement on Form S-1, Fil |
|
| January 29, 2021 |
8-K 1 ea134164-8kbiotechacq.htm CURRENT REPORT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): January 28, 2021 Biotech Acquisition Company (Exact name of registrant as specified in its charter) Cayman Islands 001-39935 N/A (State |
|
| January 29, 2021 |
Registration Rights Agreement, dated January 25, 2021, by and among the Company and the Sponsor.(1) Exhibit 10.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of January 25, 2021, is made and entered into by and among Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), and the undersigned parties listed under Investors on the signature page hereto (each, an “Investor” and collectively, the “Investors”). RECITALS WHEREAS, |
|
| January 29, 2021 |
Exhibit 10.4 BIOTECH ACQUISITION COMPANY 545 West 25th Street, 20th Floor New York, NY 10001 January 25 , 2021 Biotech Sponsor LLC 545 West 25th Street, 20th Floor New York, NY 10001 Re: Administrative Services Agreement Ladies and Gentlemen: This letter agreement by and between Biotech Acquisition Company., a Cayman Islands exempted company (the “Company”), and Biotech Sponsor LLC, dated as of th |
|
| January 29, 2021 |
EX-10.5 9 ea134164ex10-5biotechacq.htm SPONSOR WARRANTS PURCHASE AGREEMENT, DATED JANUARY 25, 2021 BY AND BETWEEN THE COMPANY AND THE SPONSOR. Exhibit 10.5 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, dated as of January 25, 2021 (as it may from time to time be amended, this “Agreement”), is entered into by and between Biotech Acquisition Compan |
|
| January 29, 2021 |
EX-10.1 5 ea134164ex10-1biotechacq.htm LETTER AGREEMENT, DATED JANUARY 25, 2021, BY AND AMONG THE COMPANY, ITS OFFICERS, ITS DIRECTORS AND THE SPONSOR Exhibit 10.1 January 25, 2021 Biotech Acquisition Company 545 West 25th Street 20th Floor New York, NY 10001 Re: Initial Public Offering Gentlemen: This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting A |
|
| January 29, 2021 |
Exhibit 1.1 UNDERWRITING AGREEMENT between BIOTECH ACQUISITION COMPANY and CANTOR FITZGERALD & CO. Dated: January 25, 2021 BIOTECH ACQUISITION COMPANY UNDERWRITING AGREEMENT New York, New York January 25, 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, Biotech Acquisition C |
|
| January 29, 2021 |
Biotech Acquisition Company Announces Pricing of $200 Million Initial Public Offering EX-99.1 10 ea134164ex99-1biotechacq.htm PRESS RELEASE, DATED JANUARY 25, 2021 Exhibit 99.1 Biotech Acquisition Company Announces Pricing of $200 Million Initial Public Offering New York, NY, January 25, 2021 – Biotech Acquisition Company (the “Company”), a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganizati |
|
| January 27, 2021 |
$200,000,000 Biotech Acquisition Company 20,000,000 Units Filed Pursuant to Rule 424(b)(4) Registration No. 333-251834 PROSPECTUS $200,000,000 Biotech Acquisition Company 20,000,000 Units Biotech Acquisition Company is a recently organized blank check company, incorporated as a Cayman Islands exempted company for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or other similar business co |
|
| January 25, 2021 |
- FOR REGISTRATION OF CERTAIN CLASSES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 Biotech Acquisition Company (Exact name of registrant as specified in its charter) Cayman Islands N/A (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identificatio |
|
| January 22, 2021 |
Biotech Acquisition Company c/o Ellenoff Grossman & Schole LLP 545 West 25th Street, 20th Floor New York, NY 10001 January 22, 2021 VIA EDGAR U. |
|
| January 22, 2021 |
January 22, 2021 VIA EDGAR U.S. Securities & Exchange Commission 100 F Street, NE Washington, D.C. 20549-4561 Re: Biotech Acquisition Company Registration Statement on Form S-1 Filed December 31, 2020, as amended File No. 333-251834 Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act of 1933, as amended (the ?Act?), the undersigned hereby joins |
|
| January 20, 2021 |
As filed with the Securities and Exchange Commission on January 19, 2021. Registration No. 333-251834 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 2 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biotech Acquisition Company (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (State or other jurisdiction of inc |
|
| January 19, 2021 |
CORRESP 1 filename1.htm Biotech Acquisition Co 545 West 25th Street, 20th Floor New York, NY 10001 VIA EDGAR January 19, 2021 U.S. Securities & Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Anuja A. Majmudar, Esq. Re: Biotech Acquisition Co. Amendment No. 1 to Registration Statement on Form S-1 Filed January 12, 2021 File No. 333-251834 Dear Ms. |
|
| January 12, 2021 |
Exhibit 10.3 INVESTMENT MANAGEMENT TRUST AGREEMENT This Investment Management Trust Agreement (this “Agreement”) is made effective as of , 2021, by and between Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Trustee”). WHEREAS, the Company’s registration statement on Form S-1, File No. 333- |
|
| January 12, 2021 |
Form of Code of Ethics and Business Conduct* EX-14 19 ea133029ex14biotechacq.htm FORM OF CODE OF ETHICS AND BUSINESS CONDUCT Exhibit 14 FORM OF CODE OF ETHICS OF BIOTECH ACQUISITION COMPANY 1. Introduction The Board of Directors (the “Board”) of Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), has adopted this code of ethics (this “Code”), as may be amended from time to time by the Board and which is applicable |
|
| January 12, 2021 |
Amended and Restated Memorandum and Articles of Association* Exhibit 3.2 THE COMPANIES ACT (2020 Revision) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM AND ARTICLES OF ASSOCIATION OF Biotech Acquisition Company (adopted by special resolution dated [Date] and effective on [date]) THE COMPANIES ACT (2020 Revision) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES AMENDED AND RESTATED MEMORANDUM OF ASSOCIATION OF Biotech Acquis |
|
| January 12, 2021 |
As filed with the Securities and Exchange Commission on January 11, 2021. Registration No. 333-251834 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biotech Acquisition Company (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (State or other jurisdiction of inc |
|
| January 12, 2021 |
Promissory Note, dated September 8, 2020, issued to Biotech Sponsor LLC EX-10.1 11 ea133029ex10-1biotechacq.htm PROMISSORY NOTE, DATED SEPTEMBER 8, 2020, ISSUED TO BIOTECH SPONSOR LLC Exhibit 10.1 THIS PROMISSORY NOTE (“NOTE”) HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). THIS NOTE HAS BEEN ACQUIRED FOR INVESTMENT ONLY AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED IN THE ABSENCE OF REGISTRATION OF THE RESALE THEREOF UNDER |
|
| January 12, 2021 |
Exhibit 10.2 [], 2021 Biotech Acquisition Company 545 West 25th Street 20th Floor New York, NY 10001 Re: Initial Public Offering Gentlemen: This letter (this “Letter Agreement”) is being delivered to you in accordance with the Underwriting Agreement (the “Underwriting Agreement”) to be entered into by and among Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), and Can |
|
| January 12, 2021 |
EX-10.5 15 ea133029ex10-5biotechacq.htm SECURITIES SUBSCRIPTION AGREEMENT, DATED SEPTEMBER 8, 2020, BETWEEN THE REGISTRANT AND BIOTECH SPONSOR LLC Exhibit 10.5 Biotech Acquisition Company 545 West 25th Street, 20th Floor New York, NY 10001 September 8, 2020 Biotech Sponsor LLC 545 West 25th Street, 20th Floor New York, NY 10001 RE: Securities Subscription Agreement Ladies and Gentlemen: This agree |
|
| January 12, 2021 |
Form of Underwriting Agreement.* Exhibit 1.1 UNDERWRITING AGREEMENT between BIOTECH ACQUISITION COMPANY and CANTOR FITZGERALD & CO. Dated: , 2021 BIOTECH ACQUISITION COMPANY UNDERWRITING AGREEMENT New York, New York [], 2021 Cantor Fitzgerald & Co. 499 Park Avenue New York, New York 10022 As Representative of the Underwriters named on Schedule A hereto Ladies and Gentlemen: The undersigned, Biotech Acquisition Company, a Cayman I |
|
| January 12, 2021 |
Form of Compensation Committee Charter ** EX-99.2 22 ea133029ex99-2biotechacq.htm FORM OF COMPENSATION COMMITTEE CHARTER Exhibit 99.2 BIOTECH ACQUISITION COMPANY COMPENSATION COMMITTEE CHARTER I. Purpose The Compensation Committee (the “Committee”) of the Board of Directors of Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), shall have responsibility for the compensation of the Company’s executive officers, |
|
| January 12, 2021 |
EX-10.8 18 ea133029ex10-8biotechacq.htm FORM OF ADMINISTRATIVE SERVICES AGREEMENT, BY AND BETWEEN THE REGISTRANT AND AN AFFILIATE OF THE REGISTRANT Exhibit 10.8 BIOTECH ACQUISITION COMPANY 545 West 25th Street, 20th Floor New York, NY 10001 [], 2021 Biotech Sponsor LLC 545 West 25th Street, 20th Floor New York, NY 10001 Re: Administrative Services Agreement Ladies and Gentlemen: This letter agreem |
|
| January 12, 2021 |
Form of Audit Committee Charter ** Exhibit 99.1 BIOTECH ACQUISITION COMPANY AUDIT COMMITTEE CHARTER I. Purpose The Audit Committee (the “Committee”) of the Board of Directors (the “Board”) of Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), shall provide assistance to the Board in fulfilling its legal and fiduciary obligations to oversee: (a) the integrity of the financial statements and other financi |
|
| January 12, 2021 |
Form of Warrant Agreement between Continental Stock Transfer & Trust Company and the Registrant* Exhibit 4.4 WARRANT AGREEMENT THIS WARRANT AGREEMENT (this “Agreement”), dated as of [], 2021, is by and between Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation, as warrant agent (the “Warrant Agent”, also referred to herein as the “Transfer Agent”). WHEREAS, the Company is engaged in an initial |
|
| January 12, 2021 |
EX-10.7 17 ea133029ex10-7biotechacq.htm FORM OF INDEMNITY AGREEMENT Exhibit 10.7 INDEMNITY AGREEMENT THIS INDEMNITY AGREEMENT (this “Agreement”) is made on , 2021. Between: (1) Biotech Acquisition Company, a Cayman Islands exempted company with its registered office at Maples Corporate Services (Cayman) Limited, PO Box 309, Ugland house, Grand Cayman KY1-1104, Cayman Islands (the “Company”); and ( |
|
| January 12, 2021 |
Exhibit 4.1 NUMBER UNITS U- SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP G1125A 124 BIOTECH ACQUISITION COMPANY UNITS CONSISTING OF ONE CLASS A ORDINARY SHARE AND ONE-HALF OF ONE WARRANT TO PURCHASE ONE CLASS A ORDINARY SHARE THIS CERTIFIES THAT is the owner of Units. Each Unit (“Unit”) consists of one (1) Class A ordinary share, of par value $0.001 per share (“Ordinary Shares”), of Biotech Acquisiti |
|
| January 12, 2021 |
Form of Registration Rights Agreement between the Registrant and certain security holders* EX-10.4 14 ea133029ex10-4biotechacq.htm FORM OF REGISTRATION RIGHTS AGREEMENT BETWEEN THE REGISTRANT AND CERTAIN SECURITY HOLDERS Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of [], 2021, is made and entered into by and among Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), and the undersigned parties list |
|
| January 12, 2021 |
Form of Sponsor Warrants Purchase Agreement between the Registrant and Biotech Sponsor LLC* Exhibit 10.6 PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT THIS PRIVATE PLACEMENT WARRANTS PURCHASE AGREEMENT, dated as of [], 2021 (as it may from time to time be amended, this “Agreement”), is entered into by and between Biotech Acquisition Company, a Cayman Islands exempted company (the “Company”), and Biotech Sponsor LLC, a Delaware limited liability company (the “Purchaser”). WHEREAS, the Com |
|
| January 12, 2021 |
Specimen Warrant Certificate (2) Exhibit 4.3 [Form of Warrant Certificate] [FACE] Number Warrants THIS WARRANT SHALL BE VOID IF NOT EXERCISED PRIOR TO THE EXPIRATION OF THE EXERCISE PERIOD PROVIDED FOR IN THE WARRANT AGREEMENT DESCRIBED BELOW BIOTECH ACQUISITION COMPANY Incorporated Under the Laws of the Cayman Islands CUSIP G1125A 116 Warrant Certificate This Warrant Certificate certifies that , or registered assigns, is the reg |
|
| January 12, 2021 |
Memorandum and Articles of Association* Exhibit 3.1 THE COMPANIES LAW (2020 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES MEMORANDUM AND ARTICLES OF ASSOCIATION OF BIOTECH ACQUISITION COMPANY Auth Code: G32395364078 www.verify.gov.ky THE COMPANIES LAW (2020 REVISION) OF THE CAYMAN ISLANDS COMPANY LIMITED BY SHARES MEMORANDUM OF ASSOCIATION OF BIOTECH ACQUISITION COMPANY 1 The name of the Company is Biotech Acquisition Compan |
|
| January 12, 2021 |
Specimen Class A Ordinary Share Certificate Exhibit 4.2 NUMBER C- SHARES SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP G1125A 108 BIOTECH ACQUISITION COMPANY INCORPORATED UNDER THE LAWS OF THE CAYMAN ISLANDS CLASS A ORDINARY SHARES This Certifies that is the owner of FULLY PAID AND NON-ASSESSABLE CLASS A ORDINARY SHARES OF THE PAR VALUE OF US$0.001 EACH OF BIOTECH ACQUISITION COMPANY (THE “COMPANY”) subject to the Company’s amended and restated |
|
| December 31, 2020 |
Exhibit 99.3 CONSENT OF AARON KIM Biotech Acquisition Company intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto the "Registration Statement"), registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Registrat |
|
| December 31, 2020 |
Exhibit 99.1 CONSENT OF BRUNO MONTANARI Biotech Acquisition Company intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto the "Registration Statement"), registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Reg |
|
| December 31, 2020 |
Exhibit 99.2 CONSENT OF PAUL BERNARD Biotech Acquisition Company intends to file a Registration Statement on Form S-1 (together with any amendments or supplements thereto the "Registration Statement"), registering securities for issuance in its initial public offering. As required by Rule 438 under the Securities Act of 1933, as amended, the undersigned hereby consents to being named in the Regist |
|
| December 31, 2020 |
Registration Statement - REGISTRATION STATEMENT As filed with the Securities and Exchange Commission on December 30, 2020. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biotech Acquisition Company (Exact name of registrant as specified in its charter) Cayman Islands 6770 N/A (State or other jurisdiction of incorporation or organizati |
|
| December 30, 2020 |
Biotech Acquisition Co 545 West 25th Street, 20th Floor New York, NY 10001 VIA EDGAR December 30, 2020 U. |
|
| November 13, 2020 |
This confidential draft submission is being submitted confidentially to the U.S. Securities and Exchange Commission on November 13, 2020 and is not being filed under the Securities Act of 1933, as amended. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biotech Acquisition Company (Exact |
|
| November 13, 2020 |
Biotech Acquisition Co 545 West 25th Street, 20th Floor New York, NY 10001 VIA EDGAR November 13, 2020 U. |
|
| September 21, 2020 |
This confidential draft submission is being submitted confidentially to the U.S. Securities and Exchange Commission on September 21, 2020 and is not being filed under the Securities Act of 1933, as amended. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biotech Acquisition Company (Exact |
